Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.14

0.0%

3:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (385)	9/29/1999 7:26:00 AM
From: Jim Oravetz	of 52153

<ENMD is due to enter the clinic shortly> Shrinking tumors. Despite its notoriety, however, endostatin isn't the first drug of its kind to be tried on human cancer patients. A similar drug, known as combrestatin, is well along in the initial phase of human testing. Both are so-called antiangiogenesis drugs, which are aimed at choking off the growth of blood vessels around a tumor, causing it to shrink. But unlike endostatin, which stops the growth of new blood vessels around the tumor, combrestatin attacks the lining of vessels that grow around tumors, shutting them down. For nine months, U.S. News followed the trials of two combrestatin volunteers to see how a test is conducted. Their experiences–one hopeful and one heartbreaking–offer a glimpse of what the endostatin trials might hold…..snip usnews.com Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next